Hitting multiple targets in HER2-positive breast cancer: Proof of principle or therapeutic opportunity?

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 4, 2011, Pages 549-565

  Geuna, Elena ^a   Milani, Andrea ^a   Redana, Stefania ^a   Rossi, Valentina ^a   Valabrega, Giorgio ^a   Aglietta, Massimo ^a   Montemurro, Filippo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Endocrine therapy; HDAC inhibitors; HER2; HSP90 inhibitors; IGF 1R; Lapatinib; mTOR inhibitors; Neratinib; Pazopanib; Pertuzumab; Trastuzumab

Indexed keywords

AFATINIB; ANASTROZOLE; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; GEFITINIB; LAPATINIB; LETROZOLE; MM 111; MONOCLONAL ANTIBODY; NERATINIB; PACLITAXEL; PANOBINOSTAT; PAZOPANIB; PERTUZUMAB; SUNITINIB; TAMOXIFEN; TANESPIMYCIN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT;

ABDOMINAL PAIN; ANEMIA; ANGIOGENESIS; ANOREXIA; APOPTOSIS; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROLIFERATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PHENOTYPE; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; PRURITUS; REVIEW; SIDE EFFECT; SKIN TOXICITY; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM STAGING; RECEPTOR, ERBB-2;

EID: 79951610766     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.525218     Document Type: Review

References (94)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37 (Pubitemid 33674041)
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82 (Pubitemid 17231334)
4. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92 (Pubitemid 32222155)
6. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74 (Pubitemid 46207001)
7. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36 (Pubitemid 46039831)
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84 (Pubitemid 41464706)
9. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009;27:5685-92
10. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43 (Pubitemid 46021510)
11. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16 (Pubitemid 44036456)
12. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28 (Pubitemid 41713383)
13. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001;61:8452-8 (Pubitemid 33131124)
14. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-61 (Pubitemid 41535366)
15. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001;28:27-32 (Pubitemid 33065107)
16. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84 (Pubitemid 47050487)
17. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27 (Pubitemid 39485684)
18. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402 (Pubitemid 47539306)
19. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41 (Pubitemid 46160912)
20. Huang X, Gao L, Wang S, et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and Insulin-like growth factor-I receptor in breast cancer cells resistant to herceptin. Cancer Res 2010;70:1204-14
21. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7 (Pubitemid 34048651)
22. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9 (Pubitemid 32691885)
23. Christianson TA, Doherty JK, Lin YJ, et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998;58:5123-9 (Pubitemid 28521172)
24. Anido J, Scaltriti M, Bech Serra JJ, et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006;25:3234-44 (Pubitemid 44106773)
25. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38 (Pubitemid 47073544)
26. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-82
27. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007;7:257-68 (Pubitemid 46192173)
28. Nahta R, Yuan LXH, Du Y, et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007;6:667-74 (Pubitemid 46332467)
29. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19:1068-74 (Pubitemid 351796331)
30. Boussen H, Cristofanilli M, Zaks T, et al. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 2010;28:3248-55
31. Fabi A, Di Benedetto A, Merola R, et al. Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer [abstract 1059]. J Clin Oncol (Meeting Abstracts) 2010;28(Suppl 15)
32. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005
33. Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009;20:1026-31
34. Lin NU, Dieras V+, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-9
35. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65 (Pubitemid 38697310)
36. Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 2009;18:1735-51
37. Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009;15:2552-8
38. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28:1301-7
39. Awada A, Dirix L, Beck J, et al. Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in ErbB2+ metastatic breast cancer [abstract 5095]. Cancer Res 2009;69(Suppl 24)
40. Chow L, Gupta S, Hershman D, et al. Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in ErbB2+ metastatic breast cancer [abstract 5081]. Cancer Res 2009;69(Suppl 24)
41. Saura C, Martin M, Moroose R, et al. Safety of neratinib (HKI-272) in combination with capecitabine in patients with solid tumors: a phase 1/2 study [abstract 5108]. Cancer Res 2009;69(Suppl 24)
42. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55:717-27
43. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28 (Pubitemid 38482068)
44. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43 (Pubitemid 47050843)
45. Gianni L, Llado A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:1131-7
46. Cortes J, Baselga J, Petrella T, et al. Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2-positive breast cancer [abstract 1022]. J Clin Oncol (Meeting Abstracts) 2009;27(Suppl 15)
47. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44
48. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/ HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11
49. Hickish T, Wheatley D, Lin N, et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab [abstract 1023]. J Clin Oncol (Meeting Abstracts) 2009;27(Suppl 15)
50. Allen LF, Eiseman IA, Fry DW, et al. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol 2003;30:65-78 (Pubitemid 37433398)
51. Rixe O, Franco SX, Yardley DA, et al. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2009;64:1139-48
52. Denlinger CS, Beeram M, Tolcher AW, et al. A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers [abstract TPS169]. J Clin Oncol (Meeting Abstracts) 2010;28(Suppl 15)
53. Arteaga CL, O'Neill A, Moulder SL, et al. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008;14:6277-83
54. Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007;13:4909-19 (Pubitemid 47294799)
55. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9 (Pubitemid 43259947)
56. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009;28:803-14
57. Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008;26:3317-23
58. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30
59. Blackwell K, Burtscher H, Sledge G, et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy [abstract 61]. Cancer Res 2009;69(Suppl 24)
60. Swaby R, Blackwell K, Jiang Z, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study [abstract 1004]. J Clin Oncol (Meeting Abstracts) 2009;27(Suppl 15)
61. Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007;99:694-705 (Pubitemid 47073531)
62. Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-6
63. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90
64. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
65. Miller K, Gianni L, Andre F, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T) [abstract 1012]. J Clin Oncol (Meeting Abstracts) 2010;28(Suppl 15)
66. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008;26:1059-65
67. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9:23-8
68. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37
69. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
70. Schwartzberg LS, Franco SX, Florance A, et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010;15:122-9
71. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26 (Pubitemid 34111379)
72. Leary AF, Drury S, Detre S, et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010;16:1486-97
73. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27 (Pubitemid 46202320)
74. Farhat MH, El-Saghir NS, Shamseddine AI. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer. Breast 2009;18:66-8
75. Hurvitz S, Pegram M, Lin L, et al. Final results of a Phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer [abstract 6094]. Cancer Res 2009;69(Suppl 24)
76. Dickler M, Franco S, Stopeck A, et al. Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC) [abstract 3133]. Cancer Res 2009;69(Suppl 2)
77. Limvorasak S, Posadas EM. Pazopanib: therapeutic developments. Expert Opin Pharmacother 2009;10:3091-102
78. Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer [abstract 1016]. J Clin Oncol (Meeting Abstracts) 2008;26(Suppl 20)
79. Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Invest Drugs 2009;18:821-34
80. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-16
81. Blay J, Lluch A, Gutierrez M, et al. Sunitinib (SU) in combination with trastuzumab (T) for the treatment of advanced breast cancer (ABC): activity and safety results from a phase II study [abstract 201]. Cancer Res 2009;69(Suppl 24)
82. Dirix L, Canon J, Amadori D, et al. An exploratory study of sunitinib (SU) plus docetaxel (D) and trastuzumab (T) for first-line therapy of HER2+ advanced breast cancer (ABC) [abstract 6088]. Cancer Res 2009;69(Suppl 24)
83. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89
84. Bender LM, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci 2008;13:3906-12 (Pubitemid 351594668)
85. Esparis-Ogando A, Ocana A, Rodriguez-Barrueco R, et al. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 2008;19:1860-9
86. Haluska P, Reinholz MM, Dueck AC, et al. N0733: phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer [abstract TPS129]. J Clin Oncol (Meeting Abstracts) 2010;28(Suppl 15)
87. Morrow PH, Wulf GM, Booser DJ, et al. Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer [abstract 1014]. J Clin Oncol (Meeting Abstracts) 2010;28(Suppl 15)
88. Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004;3:51-60 (Pubitemid 40268587)
89. Chandarlapaty S, Scaltriti M, Angelini P, et al. Inhibitors of HSP90 block p95-HER2 signaling in trastuzumab-resistant tumors and suppress their growth. Oncogene 2010;29:325-34
90. Hartmann F, Horak EM, Cho C, et al. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/ neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. Int J Cancer 1997;70:221-9 (Pubitemid 27107421)
91. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-17 (Pubitemid 350232217)
92. Saunders NA, Popa C, Serewko MM, et al. Histone deacetylase inhibitors: novel anticancer agents. Expert Opin Invest Drugs 1999;8:1611-21 (Pubitemid 29460526)
93. Swaby R, Wang M, Sparano J, et al. A phase II study of the histone deacetylase vorinostat, in combination with trastuzumab, in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer resistant to trastuzumab-containing therapy: (E1104) a trial of the Eastern Cooperative Oncology Group [abstract 5084]. Cancer Res 2009;69(Suppl 24)
94. Campone M, Conte P, Amadori D, et al. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-postive metastatic breast cancer (mBC). Preliminary safety, efficacy and pharmacokinetic results [abstract 6101]. Cancer Res 2009;69(Suppl 24)